Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, the authors examined guidelines and literature on the non-operative treatment of gender dysphoria, highlighting the importance of personalized, multidisciplinary care, and noting that such treatment is generally safe and effective according to WPATH and Endocrine Society recommendations.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

In this study, researchers found that discontinuing tamsulosin for one month before cataract surgery in rats reduces manifestations of intraoperative floppy iris syndrome, suggesting alternative preoperative treatments may be beneficial.

This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.

This report details a case of right fourth nerve palsy in a 47-year-old man following hair replacement surgery, hypothesized to be due to brainstem instability related to an anatomical variant and postoperative posture-induced cerebrospinal fluid shifts.

In this review of autonomous robotic surgery, the authors explore the integration of AI and machine learning in surgical procedures, detailing both the advancements and challenges of these technologies, including ethical concerns and current regulatory frameworks.

Serum triglyceride levels are not linked to prostate cancer risk.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

In this study, saw palmetto supplements showed varied effects on cell growth in vitro and did not significantly inhibit growth in the hamster flank organ model despite a notable trend.

This study systematically reviewed meta-analyses and Mendelian randomization studies to identify factors influencing prostate cancer risk, finding suggestive associations for physical activity, height, and smoking but no robust, convincing overlapping evidence across tested factors.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This thesis explores both environmental and genetic factors in prostate cancer, focusing on surrogate hormone markers, medical radiation, family history, and genetic polymorphisms related to DNA repair and hormone marker genes, but reports no new clinical findings.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

This review highlights that several clinical and epidemiological studies link a diet high in terpenoid compounds with a decreased risk of prostate cancer, supporting the potential use of terpenoids as therapeutic ingredients in treating this disease.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study indicates that the normal human prostate is not a major contributor to circulating blood DHT concentrations in androgen-deficient patients receiving testosterone replacement therapy.

This study demonstrates that a new Adaptive Modulation and Coding method can improve control performance in Communication-Based Train Control systems using WLAN by reducing average delay through effective transmission mode selection.

This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.

This study found that men with a cutaneous melanoma diagnosis had an increased risk of subsequently being diagnosed with prostate cancer compared to those without melanoma.

This study found that men with androgenetic alopecia at age 20 years may have a higher risk of developing aggressive prostate cancer, particularly advanced stage disease.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

This study found that keratinocyte growth factor is a potent mitogen in human hyperplastic prostate cells, suggesting it plays an important role in prostate growth by acting in a paracrine manner.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.